News

As new variant spreads, what's the latest COVID-19 vaccine guidance? It's complicated.
NB.1.8.1 is one of the latest variants of COVID-19, a "slightly upgraded version" of the LP.8.1 variant that is prominent ...
Symptoms of Nimbus COVID-19 variant: Watch out for sore throat, body-ache, fever, more
The new COVID-19 variant NB.1.8.1, known as Nimbus, is causing concern due to its subtle symptoms and high transmission rate.
GeoVax Highlights Positive Immune Response Results From GEO-CM04S1 in CLL Patients at the European Hematology Association 2025 Meeting
GEO-CM04S1 Demonstrates Superior T Cell Responses Compared to mRNA Vaccine in Phase 2 Trial Among Immunocompromised Patients ...
Changes are happening around COVID-19 vaccines: Here's what to know
The FDA plans to limit access to certain high-risk groups and also told Pfizer and Moderna to update their warning labels ...
Smithsonian Magazine on MSN18d
Six Questions About Covid-19 Vaccines, Answered
Recent vaccination announcements have led to some confusion. Four physicians weigh in on who should get vaccinated and when ...
Moderna's new COVID-19 vaccine mNexspike approved by FDA, but there's a limit on who can use it
The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as ...
McKnight's Long-Term Care News4d
2023-2024 COVID-19 vaccines show moderate protection with notable waning over time
A major new study examining the 2023-2024 COVID-19 vaccines shows moderate protection that works best in the first few months but weakens considerably over time. The research, published in JAMA ...
COVID-19 Vaccine Maker BioNTech Buys CureVac as It Aims for Cancer Treatments
CureVac shares skyrocketed 35% Thursday when the biotech firm agreed to be bought by COVID-19 vaccine maker BioNTech in an all-stock deal valued at about $1.25 billion.